First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
Authors:
- Jee-Fu HuangJHJee-Fu Huang
- Chia-Yen DaiChia-Yen Dai
- Chung-Feng HuangCHChung-Feng Huang
- Pei-Chien TsaiPei-Chien Tsai
- Ming-Lun YehMYMing-Lun Yeh
- Po-Yau HsuPHPo-Yau Hsu
- Shiu-Feng HuangSHShiu-Feng Huang
- Ming-Jong BairMBMing-Jong Bair
- Nai-Jen HouNHNai-Jen Hou
- Ching-I HuangCHChing-I Huang
- Po-Cheng LiangPLPo-Cheng Liang
- Yi-Hung LinYLYi-Hung Lin
- 12 August 2021
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 15 (5) , 1136-1147
Abstract
Background The efficacy and safety of insulin sensitizer in Asians with non-alcoholic steatohepatitis (NASH) remain elusive. Aims The double-blind, randomized, placebo-controlled trial was conducted aiming to investigate the efficacy and safety of pioglitazone in NASH patients. Methods A total of 90 NASH patients (66 males, age = 44.1 ± 12.7 years) were prospectively randomized into oral pioglitazone 30 mg/day (Arm A) or placebo (Arm B) for 24 weeks. The primary endpoint was the efficacy of pioglitazone in reducing inflammation and liver fat at end-of-treatment (EOT). NASH resolution/improvement without fibrosis worsening was also evaluated. Results At EOT, there was a significantly decline of alanine aminotransferase (86.9 ± 34.3 to 45.7 ± 35.8 IU/L, p = 0.003) level in Arm A patients. In intention-to-treat analysis among 66 patients who completed paired biopsies, The NAFLD activity score (NAS) of 30 Arm A patients significantly decreased from 4.27 ± 1.14 at baseline to 2.53 ± 1.63 at EOT (p < 0.0001), whereas there was no significant change in patients of Arm B (3.94 ± 1.41 vs 3.94 ± 1.51, p = 1.0). NASH improvement without worsening of fibrosis was achieved in 46.7% (14/30) patients in Arm A, compared to 11.1% (4/36) patients in Arm B (p = 0.002). Liver fat content reduced (20.2 ± 9.0 to 14.3 ± 6.9%, p < 0.0001) on MRI–PDFF in Arm A compared to their counterparts. No significant difference of adverse events occurred between groups. Conclusions A 24-week pioglitazone treatment was well-tolerated and effective in improving liver histology and reducing liver steatosis in Asian NASH patients. (ClinicalTrials.gov number: NCT01068444)Keywords
All Related Versions
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 107-2314-B-037-083-MY3)
- Kaohsiung Medical University (KMU-TC108A04-3, KMU-TC109B05)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH106-6R08, KMUH107-7R05)
This publication has 29 references indexed in Scilit:
- Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liverBMC Medical Genetics, 2013
- Prevalence and risk factors for non‐alcoholic fatty liver disease in Asian people who are not obeseJournal of Gastroenterology and Hepatology, 2012
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Metabolic syndrome and its components after liver transplantation: Incidence, prevalence, risk factors, and implicationsClinical Nutrition, 2010
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- Role of ChREBP in hepatic steatosis and insulin resistanceFEBS Letters, 2007
- Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular eventsLiver Transplantation, 2007
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2006
- Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological ImprovementClinical Gastroenterology and Hepatology, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006